Select Language

LOXL2

LOXL2 Overview

English Name	Lysyl oxidase homolog 2	Approved Drugs	0
Drugs in Clinical Trials	1	Target Synonym	EC:1.4.3.13，EC 1.4.3，Lysyl oxidase-like protein 2，Lysyl oxidase homolog 2，LOXL2，Lysyl Oxidase Like 2，Lysyl Oxidase-Related Protein WS9-14，Lysyl Oxidase-Related Protein 2，Lysyl Oxidase-Like 2 Delta E13，Lysyl Oxidase-Like 2 Protein，Lysyl Oxidase Related 2，Lysyl Oxidase-Like 2，EC 1.4.3.13，WS9-14，LOR2，LOR
Highest Development Stage	Phase 2 Clinical

English Name	Lysyl oxidase homolog 2
Target Synonym	EC:1.4.3.13，EC 1.4.3，Lysyl oxidase-like protein 2，Lysyl oxidase homolog 2，LOXL2，Lysyl Oxidase Like 2，Lysyl Oxidase-Related Protein WS9-14，Lysyl Oxidase-Related Protein 2，Lysyl Oxidase-Like 2 Delta E13，Lysyl Oxidase-Like 2 Protein，Lysyl Oxidase Related 2，Lysyl Oxidase-Like 2，EC 1.4.3.13，WS9-14，LOR2，LOR
Approved Drugs	0
Drugs in Clinical Trials	1
Highest Development Stage	Phase 2 Clinical

LOXL2 Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag & Avi Tag (1)His Tag (1)
Conjugate
Biotin-labeled (1)Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
LO2-H52H3	Human	HEK293	Human LOXL2 Protein, His Tag (active enzyme)
LO2-H82E3	Human	HEK293	Biotinylated Human LOXL2 Protein, His,Avitag™ (active enzyme)

Total: 2

LOXL2 Background

Lysyl oxidase homolog 2 is also known as LOXL2, Lysyl oxidase-like protein 2, which is expressed in many tissues, highest expression in reproductive tissues, placenta, uterus and prostate, Up-regulated in a number of cancers cells and tissues. LOXL2 mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. LOXL2 acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. LOXL2 acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.